FIELD: pharmacology.
SUBSTANCE: invention relates to a preparation for treatment of receptor-mediated chemokine C-X-C type 5 (CXCR5) diseases. The drug contains approximately 5 mg/ml to approximately 100 mg/ml of IgG4 antibody that binds to the chemokine C-X-C type 5 receptor (CXCR5) and approximately 5 to approximately 50 mM of citrate as a buffer. The pH of the preparation is at or below the pH value of about 6, as well as the pI of the antibody.
EFFECT: obtaining of a stable preparation that can be used for treatment of chemokine C-X-C type 5 receptor mediated diseases.
9 cl, 38 dwg, 117 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY FORMULATIONS | 2017 |
|
RU2769326C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO LAG-3 AND ITS USE | 2018 |
|
RU2771384C2 |
| COMPOSITIONS BASED ON BISPECIFIC ANTIBODIES TO IL-4/IL-13 | 2014 |
|
RU2690850C2 |
| PHARMACEUTICAL FORMULATION CONTAINING ADVANCED ANTIBODY MOLECULES | 2010 |
|
RU2565809C2 |
| METHODS AND COMPOSITIONS INCLUDING PURIFIED RECOMBINANT POLYPEPTIDES | 2014 |
|
RU2793783C1 |
| STABLE LIQUID PREPARATION OF ANTIBODY | 2009 |
|
RU2518278C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODIES AGAINST CD40 AND APPLICATION THEREOF | 2019 |
|
RU2778572C1 |
| COMPOSITIONS OF ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2772781C2 |
| ANTIBODY CONTAINING PREPARATION | 2017 |
|
RU2748046C2 |
| HUMANIZED IMMUNE BODIES FOR CXCR5, THEIR SECONDARIES, AND THEIR USE | 2008 |
|
RU2571515C2 |
